07:56 AM EDT, 08/26/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Tuesday said the mechanism of action of its next generation personalized off-the-shelf immunotherapy has been published in the peer-reviewed open-access journal, JCI Insight.

The research, which was conducted in collaboration with the National Cancer Institute (NCI), validates the core design principle behind Bria-OTS+ platform, a statement said.

"These data are consistent with the encouraging clinical results we recently reported in our Phase 1/2a study in metastatic breast cancer and provide important insights into the mechanism of action of our cellular immunotherapy platform technology," said Dr. William Williams, BriaCell's president and CEO.

BriaCell shares closed 9.6% higher, to $10.41, on the Toronto Stock Exchange, on Monday.